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1  |  INTRODUC TION
Iatrogenic preterm delivery, also called provider- initiated preterm 
birth, is defined as a birth that occurs before 37 weeks of gestation 
due to a planned delivery (induction of labor or cesarean section 
in the absence of spontaneous labor or rupture of membranes). 
According to reports, iatrogenic preterm delivery constitutes ap-
proximately 30%– 35% of all preterm deliveries and may vary ac-
cording to the region.1- 4 In the past decades, the rates of iatrogenic 
preterm deliveries have been increasing. As a result, it has become 
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Abstract
Iatrogenic preterm birth is a planned delivery that occurs before 37 weeks of gesta-
tion due to maternal and/or fetal causes. However, in some cases, such deliveries 
also occur with no apparent medical indication. The increasing numbers of iatrogenic 
preterm deliveries worldwide have led researchers to identify modifiable causes that 
allow the formulation of preventive strategies that could impact the overall preterm 
birth rate. The present document contains the FIGO (International Federation of 
Gynecology and Obstetrics) Working Group for Preterm Birth recommendations, aim-
ing to reduce the rates of iatrogenic preterm birth based on four of the most common 
clinical scenarios and issues related to iatrogenic preterm delivery. The working group 
supports efforts to identify the contribution of iatrogenic preterm delivery to the 
overall preterm birth rate and encourages health authorities to establish preventive 
measures accordingly. We encourage care providers to maintain single embryo trans-
fer policies to prevent multiple pregnancies as a substantial contributor of iatrogenic 
preterm birth. The working group also recommends that efforts to reduce unneces-
sary cesarean sections must be warranted, and mechanisms to ensure the appropriate 
time of delivery and strengthening of education and communication processes must 
be pursued.
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the leading cause of preterm delivery in some countries, reaching 
almost 50% of all preterm births.2- 5
The causes of iatrogenic delivery vary according to the region of 
the world, but in general they can be divided into four main groups:
• obstetric complications (e.g. hypertensive disorders of pregnancy, 
placental conditions, antepartum hemorrhage)
• fetal causes (e.g. fetal distress, fetal growth restriction, structural 
malformations)
• maternal medical conditions (e.g. heart disease, nephropathy, 
cancer, sepsis)
• non- medically indicated iatrogenic preterm delivery.2,5
The incidence of iatrogenic preterm delivery is increasing world-
wide. Some of the factors that may influence this phenomenon in-
clude the increase in maternal age, which is associated with more 
significant comorbidities and obstetric complications; the increase in 
the prevalence of obesity; the use of assisted reproductive techniques 
with the consequent rise in multiple pregnancies, which also carries 
an increased risk of obstetric complications in singleton pregnancies, 
including an increased rate of cesarean delivery— a risk factor for sub-
sequent complications such as placenta previa and placenta accreta.2,6 
In addition, doctors’ behavior also plays a role, as some obstetricians 
underestimate the risks of preterm delivery.
In some countries and regions, the main contributors of iatrogenic 
delivery have been identified and reported. For example, in China, 
causes such as hypertensive disorders of pregnancy, placenta previa, 
and multiple pregnancy are the most frequent, whereas in Brazil, hy-
pertensive disorders of pregnancy, placental abruption, and diabetes 
play a significant role in the number of iatrogenic preterm births.7,8 
Based on these data, strategies have been proposed to address poten-
tially modifiable risk factors for iatrogenic preterm delivery in order to 
reduce iatrogenic preterm delivery.8,9
2  |  CLINIC AL SCENARIOS AND ISSUES
2.1  |  Iatrogenic preterm delivery for maternal, 
medical, and obstetric complications
Some pre- existing maternal conditions and obstetric complications 
may require delivery before 37 weeks of gestation to ensure the 
safety of the mother and/or the baby. However, the evidence sup-
porting recommendations for the timing of delivery for most of 
these conditions is limited and primarily based on expert consen-
sus. Therefore, this decision- making process often requires indi-
vidualization. The prevalence of the different causes of iatrogenic 
preterm delivery varies depending on world region.1,4 However, 
some of the most common maternal medical conditions and ob-
stetric complications that may require indicated preterm birth are:
• hypertensive disorders of pregnancy
• placental and umbilical cord anomalies.
Preventing the conditions mentioned above is an ongoing chal-
lenge. Strategies such as reducing cesarean delivery rates would 
probably have an impact on the incidence of placenta previa or 
accreta; policies to reduce obesity in women would decrease the 
rates of gestational diabetes; and appropriate screening and use of 
low- dose aspirin in selected populations has been proven to reduce 
the prevalence of pre- eclampsia.10 However, there are reasons to 
believe that doctors’ attitudes and clinical behavior are the most 
critical factors.
Recommendation: Efforts should be directed to identifying the con-
tribution of iatrogenic preterm delivery to the overall rate of preterm de-
livery and its causes in each country. We encourage health authorities to 
establish action plans, screening programs, evidence- based preventive 
measures, and health policies to target modifiable risk factors to prevent 
iatrogenic preterm delivery.
2.2  |  Iatrogenic preterm delivery for fetal causes
Fetal development is a complex process that involves the interaction 
of genetic and environmental factors. Alterations at any step along 
the way can lead to fetal complications that may require early deliv-
ery to improve the chances of a healthy child. Fetal conditions such as 
fetal distress and fetal growth restriction secondary to impaired pla-
cental function and monochorionic multiple pregnancies are among 
the most common fetal causes of iatrogenic preterm delivery.
Preventing fetal causes of preterm delivery requires further re-
search. However, assisted reproductive technologies have led to an 
increase in multiple pregnancies and, therefore, a related increase in 
preterm birth rates. Singleton pregnancies conceived using assisted 
reproductive technologies are also at increased risk of pregnancy 
complications. According to the Human Multiple Births Database, 
the global twin rate increased by a third (9.1 to 12.0/1000 deliver-
ies) between 1980– 1985 and 2010– 2015.11 The clinical impact of 
the increase of multiple pregnancies in terms of preterm birth, as 
reported by the Centers for Disease Control and Prevention (CDC), 
is that three of every five twin babies are born preterm (six times 
the rate for singletons) and one of every four preterm twins is ad-
mitted to the neonatal intensive care unit (five times the rate for 
singletons). Therefore, optimizing assisted reproductive technolo-
gies is a mandatory step toward reducing iatrogenic prematurity, 
particularly the adoption of single embryo transfer.
Recommendation: Continue and strengthen policies such as single 
embryo transfer to regulate assisted reproductive technologies world-
wide, and promote and support research to understand and prevent fetal 
causes of preterm birth.
2.3  |  Recommendation for the timing of iatrogenic 
delivery for common pregnancy conditions
While in each pregnancy the mother and fetus require individu-
alized care, a general rule can be defined for common pregnancy 
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conditions. These rules are based on large randomized clinical trials 
conducted in recent years comparing induction of labor and expect-
ant management. As is apparent from Table 1, iatrogenic delivery 
is not required for any of the common pregnancy conditions and 
appropriate monitoring is advised instead, perhaps with the excep-
tion of pre- eclampsia, in which delivery between 34 and 37 weeks 
can be considered,12,13 while for women with chronic hypertension 
the recommendation based on non- randomized data is 38 weeks.14 
In pregnancies complicated by growth restriction at term, the 
DIGITAT study showed that the optimal timing of induction is 
around 38 weeks,15 while in pregnancies with early- onset growth 
restriction without fetal distress, earlier induction does not improve 
outcomes.16 Similarly, for pregnancies complicated by macrosomia, 
induction of labor at 38 weeks improved outcomes compared to 
expectant management.17 While RCTs are lacking for studies com-
plicated by diabetes, it can be assumed that in the presence of mac-
rosomia, induction of labor at 38 weeks improves outcomes.
For pregnancies complicated by preterm prelabour rupture of 
membranes (PPROM) without GBS or other signs of infection, ex-
pectant management until 37 weeks improves neonatal respiratory 
outcomes.18 Careful monitoring for signs of infection is warranted 
as women with PPROM between 34 + 0/7 and 36 + 6/7 weeks who 
undergo expectant management are more likely to have an antepar-
tum hemorrhage or chorioamnionitis.18 For women with uncompli-
cated twin pregnancies, individual participant data meta- analysis of 
cohort studies shows the optimal timing of delivery to be 37 weeks 
for dichorionic pregnancy and 37 weeks + 0 days for monochori-
onic pregnancy.19 Finally, in women with uncomplicated singleton 
pregnancies, two large RCTs definitively showed that induction of 
labor should be offered at 41 weeks,20 whereas the ARRIVE study 
suggests that induction of labor at 39 weeks improves outcomes.21
Three things should be stressed. First, and most important, these 
are general rules of thumb for pregnancies complicated by a condition 
but with otherwise non- compromised mother and fetuses. Of course, 
individual findings regarding the condition of the mother or fetus jus-
tify earlier delivery. Second, apart from pre- eclampsia, all recommended 
gestational ages are at or beyond 37 weeks, which should stimulate 
careful consideration around scheduling women for iatrogenic preterm 
delivery. Third, it should be considered that progression of pregnancy, in 
general, improves cognitive performance of the offspring.22
2.4  |  Previous cesarean delivery and 
preterm delivery
Cesarean delivery (CD) rates have increased worldwide over the past 
decades, particularly in middle- and high- income countries. It has been 
reported that between 1990 and 2014 the global average CD rate in-
creased 12.4% (from 6.7% to 19.1%), with an average annual increase of 
4.4%.23 In the secondary analysis of the Multicountry Survey on Maternal 
and Newborn Health (WHOMCS), the WHO has demonstrated that pre-
vious cesarean deliveries are associated with increased risk of preterm 
birth and complications that lead to preterm delivery, such as uterine 
rupture (aOR 7.7; 95% CI 5.5– 10.9), morbidly adherent placenta (aOR 
2.6; 95% CI 2.0– 3.4), and placenta previa (aOR 1.8; 95% CI 1.5– 2.1).23,24
The reasons for the increase in cesarean rates are multifacto-
rial and poorly understood. However, factors that may play an es-
sential role for some countries are health systems dynamics and 
limited resources, making caesarean delivery a more convenient 
mode of delivery, sociocultural issues like women's fear of pain or 
pelvic relaxation after vaginal delivery, and maternal and clinician 
preferences.
Recommendation: To reduce preterm delivery related to previous 
cesarean complications, efforts should be made on a multilevel basis to 
avoid unnecessary cesarean sections.
3  |  NONMEDIC ALLY-  INDIC ATED 
PRETERM DELIVERY
In some studies, and particularly in low- and middle- income coun-
tries, there is a significant percentage of iatrogenic deliveries be-
tween 34 and 36 weeks.4,5 However, a clear indication is not always 
recorded. This happens due to the absence of, or lack of adherence 
TA B L E  1  Indicative gestational age of delivery for different pregnancy complications
Condition
Gestational age 
recommended for planned 
delivery Evidence from literature
Pregnancy- induced hypertension 39 weeks HYPITAT I and II12
Pre- eclampsia 34– 37 weeks HYPITAT I and II12 Phoenix13
Chronic hypertension 38 weeks Population- based study14
Fetal growth restriction without fetal distress 38 weeks DIGITAT,15 GRIT16
Large baby (including diabetes) 38 weeks DAME17
Preterm Prelabour Rupture of Membranes (PPROM) (without GBS) 37 weeks PROMPT, PROMEXIL I & II18
Uncomplicated dichorionic twin pregnancy 37 weeks Individual participant data meta- analysis19
Uncomplicated monochorionic twin pregnancy 37 weeks and 0 days Individual participant data meta- analysis19
Uncomplicated singleton pregnancy 41 weeks Index and Swepis,20 ARRIVE21
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to, clinical practice guidelines, or practice based on personal ex-
perience rather than evidence- based for the treatment of medical 
complications. It is well known that the morbidity of a late preterm 
infant born between 34 and 36 weeks of gestation is seven times 
greater than a full- term infant.1,2 Therefore, the decision to deliver 
a preterm infant should balance the risks of morbidity and perina-
tal mortality of prematurity against the possible maternal and fetal 
consequences of continuing a pregnancy. One of the strategies aim-
ing to reduce the number of late iatrogenic preterm and early- term 
births is elective induction of labor and elective cesarean section 
after 39 weeks of gestation.25 This policy has been adopted and 
proven successful in countries like the United States.26
Another cause of iatrogenic preterm delivery could be the lack 
of appropriate dating of pregnancy. It is well known that the first tri-
mester ultrasound, when performed by properly trained personnel, 
constitutes the most accurate method to estimate gestational age. 
However, in the absence of a proper ultrasound examination before 
22 + 0 weeks of gestation, the pregnancy is considered as subopti-
mally dated and therefore at greater risk for iatrogenic preterm birth.27
Recommendation: Mechanisms for implementing and ensuring a first 
trimester ultrasound for appropriate dating of pregnancy as well as ad-
herence to clinical practice guidelines for appropriate delivery timing in 
different medical, fetal, and obstetrical conditions should be considered. 
Strengthening the patient education and communication processes to 
achieve good decision- making processes must be pursued.
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